Clinical Trial

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

Recruiting
View on ClinicalTrials.gov →
Summary
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-11
Trial Details
NCT Number NCT07544862
Lead Sponsor Chengdu Kangnuoxing Biopharma,Inc.
Conditions Atopic Dermatitis (AD)
Enrollment 1,000 participants
Start Date 2026-06-02
Primary Completion 2027-12 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-10